%0 Journal Article
%T A journey from basic stem cell discovery to clinical application: the case of adventitial progenitor cells.
%A Spencer HL
%A Slater SC
%A Rowlinson J
%A Morgan T
%A Culliford LA
%A Guttridge M
%A Emanueli C
%A Angelini G
%A Madeddu P
%J Regen Med
%V 10
%N 1
%D 2015
%M 25562351
%F 3.21
%R 10.2217/rme.14.64
%X Ischemia is a leading cause of death in the western world. Regenerative medicine aims to improve healing of ischemic injury by complementing pharmacologic/interventional treatments. Navigating regenerative therapies from 'bench-to-bedside' is a multistep time-consuming process, balancing cell expansion, purity, safety and efficacy while complying with regulatory guidelines. Studies started in academic laboratories unused to long-term planning often fail because of poor strategy design, lack of contingency plans or funding. We provide a strategic insight into our translation of saphenous vein-derived adventitial progenitor cells into a clinical grade product to treat angina. We discuss discovery phases, introduction of standard operating procedures and upgrade to clinical standards. We also examine contractual aspects of transferring to GMP-accredited facilities for clinical production and unexpected hurdles.